Anxiety Drug Pregabalin Linked to Rising Number of Deaths – Here’s What You Should Know
Rising deaths from pregabalin, also used for restless legs syndrome, spotlight the need for drug interaction knowledge to protect patients.
Rising deaths from pregabalin, also used for restless legs syndrome, spotlight the need for drug interaction knowledge to protect patients.
Zevra Therapeutics highlighted the heart safety of serdexmethylphenidate, the main ingredient in KP1077, its potential treatment for idiopathic hypersomnia, during a poster presentation at Psych Congress 2023.
With new narcolepsy drugs available—and more in the pipeline—sleep specialists face the challenge of selecting the most suitable therapies for their patients.
Harmony Biosciences reported second-quarter business updates, showcasing an upswing in prescription demand for its narcolepsy drug, Wakix.
Read MoreSodium oxybate oral solution is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness in patients aged 7 and older with narcolepsy.
Read MoreThe approval makes pitolisant the first and only treatment drug approved in mainland China for narcolepsy.
Read MoreChildren with attention-deficit hyperactivity disorder (ADHD) and treated with the ADHD medication Azstarys showed statistically significant and lasting improvements in their sleep in a yearlong study.
Read MoreA patient with type 2 narcolepsy reports an experience to her sleep physician that was not seen in any of the clinical trials.
Read MoreThe presentations include data from the SHARP study in patients with excessive daytime sleepiness associated with OSA, real-world data from OSA patients taking Sunosi as part of the SURWEY study in Germany, healthcare resource use in OSA patients with residual EDS, and effect sizes and numbers needed to treat analyses.
Read MoreTokyo-based Eisai will present eight poster presentations, including the latest data on its in-house discovered orexin receptor antagonist lemborexant (Dayvigo) at SLEEP 2023.
Read MoreAvadel Pharmaceuticals will present new data supporting the clinical profile for Lumryz for narcolepsy in 12 abstracts at SLEEP 2023.
Read MoreFrom sleep trackers to wakefulness drugs, the 21st century has seen an influx of new technology that could radically alter the way we sleep.
Read MoreAxsome Therapeutics will present data on Sunosi, including results from the SHARP study, at the American Society of Clinical Psychopharmacology Annual Meeting, being held May 30 to June 3.
Read MoreNew research examines the mortality and exacerbation risks associated with non-benzodiazepine benzodiazepine receptor agonists versus other hypnotics to treat insomnia in COPD patients.
Read MoreThe FDA says current prescribing information for some prescription stimulants does not provide up-to-date warnings about the harms of misuse and abuse.
Read MoreJazz Pharmaceutics says the benefits of reducing sodium intake resonate with prescribers as the large majority of new-to-oxybate narcolepsy patients continue to be prescribed Xywav.
Read MoreIn a study comparing the effectiveness of wakefulness-promoting agents, researchers pinpointed which drug is likely the most effective in treating excessive daytime sleepiness for people with sleep apnea.
Read MorePhysicians who regularly manage RLS patients offer real-world advice on ways to prevent augmentation. For patients already experiencing augmentation, new therapy options may be on the way.
Read More